T 3762

Known as: T-3762 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2002
024619982002

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
We studied the effect of pazufloxacin mesilate (T-3762), a new fluoroquinolone for intravenous administration, on the serum… (More)
Is this relevant?
Review
2000
Review
2000
Toyama Chemical Co Ltd is developing pazufloxacin (T-3761), an orally active synthetic quinolone antibiotic, which is awaiting… (More)
Is this relevant?
1999
1999
T-3762 is an injectable new quinolone with a broad spectrum of antibacterial activity. Pazufloxacin (T-3761) is an active form of… (More)
Is this relevant?
1998
1998
A teratogenicity study of T-3762, an injectable new quinolone antibacterial agent, was conducted in Sprague-Dawley rats to… (More)
Is this relevant?
1998
1998
A three months intravenous repeated dose toxicity study of T-3762, a novel parenteral quinolone antibacterial agent, was carried… (More)
Is this relevant?
1998
1998
T-3762, a newly developed fluoroquinolone antimicrobial agent, ciprofloxacin (CPFX) and ofloxacin (OFLX) were administered… (More)
Is this relevant?
1998
1998
Fluoroquinolone antibiotics and chemically related compounds including the pazufloxacin methanesulfonate named T-3762 were… (More)
Is this relevant?
1998
1998
A thirteen-week intravenous repeated dose toxicity study of T-3762, parenteral quinolone antimicrobial agent, and four-week… (More)
Is this relevant?
1998
1998
Single dose intravenous toxicity studies of T-3762, a novel parenteral quinolone antimicrobial agent, were conducted in rats… (More)
Is this relevant?
1998
1998
To predict the actions of T-3762, a newly developed fluoroquinolone antimicrobial agent, as well as ciprofloxacin (CPFX) and… (More)
Is this relevant?